Rallybio Corporation
NASDAQ:RLYB
0.5366 (USD) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0.636 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.131 | 0.15 | 0.167 | 0.109 | 0.062 | 0.026 |
| Gross Profit
| 0.636 | -0.15 | -0.167 | -0.109 | -0.062 | -0.026 |
| Gross Profit Ratio
| 1 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 41.507 | 53.394 | 40.689 | 26.909 | 17.63 | 11.366 |
| General & Administrative Expenses
| 19.625 | 25.388 | 27.195 | 18.739 | 7.673 | 6.276 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 19.625 | 25.388 | 27.195 | 18.739 | 7.673 | 6.276 |
| Other Expenses
| 0 | 0.15 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 61.132 | 78.932 | 67.884 | 45.648 | 25.303 | 17.642 |
| Operating Income
| -60.496 | -78.932 | -67.884 | -45.648 | -25.303 | -17.642 |
| Operating Income Ratio
| -95.119 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.721 | 4.368 | 1.23 | -1.365 | -1.159 | 0.182 |
| Income Before Tax
| -57.775 | -74.564 | -65.579 | -45.508 | -24.94 | -17.46 |
| Income Before Tax Ratio
| -90.841 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -2.239 | -2.041 | 0 | 0 | -0.015 | 0.166 |
| Net Income
| -57.775 | -74.564 | -66.487 | -47.01 | -26.447 | -17.626 |
| Net Income Ratio
| -90.841 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.33 | -1.84 | -2.09 | -1.46 | -1.19 | -0.55 |
| EPS Diluted
| -1.33 | -1.84 | -2.09 | -1.46 | -1.19 | -0.79 |
| EBITDA
| -60.496 | -72.373 | -65.412 | -45.389 | -24.829 | -17.395 |
| EBITDA Ratio
| -95.119 | 0 | 0 | 0 | 0 | 0 |